A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

Strathcona Resources (OTCPK:STHRF) said Friday it formally launched its offer to acquire MEG Energy (OTCPK:MEGEF) that values ...

Income investing isn’t meant to create fabulous wealth in a month or even a year. After a quarter-century of successful ...

Stocks were boosted in May by easing trade tensions, solid corporate earnings and signs the U.S. economy remains resilient ...

Novo Nordisk (NYSE: NVO) and Cava Group (NYSE: CAVA) are excellent choices. Novo Nordisk's shares have significantly lagged ...

Stephanie Walker was diagnosed with metastatic breast cancer (MBC) nearly a decade ago — an experience she says transformed ...

Misinterpretation of MRI findings by clinicians focused on earlier intervention is leading to increased rates of ...

Eli Lilly has morphed from a reliable pharma giant into a biotech powerhouse riding blockbuster success. Mounjaro and ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...